ReviewNeurosurgical review2016
The molecular aspects of chordoma.
Review in Neurosurgical review, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Pre-Spondylectomy Radiofrequency Ablation for Spinal Chordoma: An Illustrative Case and Systematic Review of Clinical Applications and Outcomes.Current oncology (Toronto, Ont.) · 2026Pooled it
- Exploring perspectives on skull base chordoma management: a modified Delphi approach to consensus.Journal of neuro-oncology · 2025Article
- SMARCB1 orchestrates cellular plasticity and oncogenic pathways in typical and chondroid chordomas.Scientific reports · 2025Article
- Advancing Precision Medicine: The Role of Genetic Testing and Sequencing Technologies in Identifying Biological Markers for Rare Cancers.Cancer medicine · 2025Review
- Chordoma Spontaneous Regression After COVID-19.Viruses · 2024Article
- Prognostic factors and overall survival in pelvic Ewing's sarcoma and chordoma: A comparative SEER database analysis.Heliyon · 2024Article
- Primary lung chordoma: a case report.Diagnostic pathology · 2024Article
- Unusual Presentation of Thoracic Chordoma with Spinal Epidural Hematoma: A Rare Case Report and PRISMA-Driven Systematic Review.Clinical medicine insights. Case reports · 2024Article
- Activation of Wnt Pathway Suppresses Growth of MUG-Chor1 Chordoma Cell Line.Cell biochemistry and biophysics · 2023Article
- Impact of silencing eEF2K expression on the malignant properties of chordoma.Molecular biology reports · 2023Article
- The malignancy of chordomas is enhanced via a circTLK1/miR-16-5p/Smad3 positive feedback axis.Cell death discovery · 2023Article
- Sclerotic lumbar chordoma: A case report.Radiology case reports · 2022Article
- Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas.Cancer immunology, immunotherapy : CII · 2022Article
- XIST sponges miR-320d to promote chordoma progression by regulating ARF6.Journal of bone oncology · 2022Article
- Bibliometric analysis of the global research trends and hotspots in chordoma from 2000 to 2020.PloS one · 2022Article
- Long non-coding RNA KRT8P41/miR-193a-3p/FUBP1 axis modulates the proliferation and invasion of chordoma cells.Journal of bone oncology · 2021Article
- Clinical management of pediatric chordomas: a comprehensive review.Acta neurologica Belgica · 2021Review
- LncRNA-NONHSAT024778 promote the proliferation and invasion of chordoma cell by regulating miR-1290/Robo1 axis.International journal of biological sciences · 2021Article
- Unusual extradural chordoma in an adolescent presenting with lumbar radiculopathy.BMJ case reports · 2020Article
- LncRNA XIST Promotes Growth of Human Chordoma Cells by Regulating miR-124-3p/iASPP Pathway.OncoTargets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chordomas are one of the rarest bone tumors, and they originate from remnants of embryonic notochord along the spine, more frequently at the skull base and sacrum. Although they are relatively slow growing and low grade, chordomas are highly recurrent, aggressive, locally invasive, and prone to metastasize to the lungs, bone, and the liver. Chordomas highly and generally show a dual epithelial-mesenchymal differentiation. These tumors resist chemotherapy and radiotherapy; therefore, radical surgery and high-dose radiation are the most used treatments, although there is no standard way to treat the disease. The molecular biology process behind the initiation and progression of a chordoma needs to be revealed for a better understanding of the disease and to develop more effective therapies. Efforts to discover the mysteries of these molecular aspects have delineated several molecular and genetic alterations in this tumor. Here, we review and describe the emerging insights into the molecular landscape of chordomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.